The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety and efficacy of eflapegrastim in reducing severe neutropenia in patients treated with myelosuppressive chemotherapy in a phase 3 randomized controlled trial compared to pegfilgrastim (ADVANCE trial).
 
Lee Steven Schwartzberg
Honoraria - Amgen; NanoString Technologies; Novartis; Pfizer
Consulting or Advisory Role - Bristol-Myers Squibb; Caris Life Sciences; Genomic Health; Helsinn Therapeutics; Pfizer; Spectrum Pharmaceuticals; Tesaro
 
Zandong Yang
Employment - Spectrum Pharmaceuticals
Stock and Other Ownership Interests - Spectrum Pharmaceuticals
Travel, Accommodations, Expenses - Spectrum Pharmaceuticals
 
Julio Antonio Peguero
No Relationships to Disclose
 
Richy Agajanian
Research Funding - Spectrum Pharmaceuticals
 
Jayaram S. Bharadwaj
Research Funding - Spectrum Pharmaceuticals
 
Alvaro Restrepo
Research Funding - Spectrum Pharmaceuticals
 
Osama Hlalah
Research Funding - Spectrum Pharmaceuticals
 
Inderjit Mehmi
Speakers' Bureau - Bristol-Myers Squibb
 
Gajanan Bhat
Employment - Spectrum Pharmaceuticals
Stock and Other Ownership Interests - Spectrum Pharmaceuticals
Travel, Accommodations, Expenses - Spectrum Pharmaceuticals
 
Patrick Wayne Cobb
Stock and Other Ownership Interests - Abbott Laboratories; Abbvie; Amgen; Array BioPharma; Boston Scientific; Johnson & Johnson; Medtronic; Merck; United Health Group
Honoraria - Oncology Business Review
Consulting or Advisory Role - Spectrum Pharmaceuticals
Research Funding - Acerta Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celgene (Inst); EMD Serono (Inst); Galera Therapeutics (Inst); Genentech/Roche (Inst); GTx (Inst); Incyte (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Pharmacyclics (Inst); Sanofi (Inst); Seagen (Inst); Spectrum Pharmaceuticals (Inst); Takeda (Inst); TG Therapeutics (Inst); United Therapeutics (Inst)